secwatch.observer — SEC 8-K summary
======================================

Issuer:     HAEMONETICS CORP (HAE)
CIK:        0000313143
Form:       8-K
Filed at:   2023-10-10T23:59:59+00:00
Accession:  0000313143-23-000048
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Haemonetics to acquire OpSens for CAD $2.90/share in cash, expected close by March 31, 2024
--------------------------------------------------------------------------------

- Haemonetics (HAE) will pay CAD $2.90 per share for all OpSens common shares via a plan of arrangement under Québec law.
- Closing conditions include 2/3 shareholder vote, HSR and Investment Canada approvals, court order, and no material adverse effect.
- OpSens directors and officers owning ~4.75% of shares have agreed to vote in favor via voting agreements.
- If OpSens terminates for a superior proposal or changes recommendation, it pays Haemonetics a CAD $12.075M termination fee.
- The transaction must close by March 31, 2024, with an automatic 75-day extension if regulatory approvals are not yet obtained.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/313143/000031314323000048/0000313143-23-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/313143/000031314323000048/hae-20231010.htm
  HTML page:      https://secwatch.observer/filing/0000313143-23-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer